Pharmaceutical nanotechnology最新文献

Rheumatoid Arthritis (RA) is a chronic autoimmune disorder characterized by inflammation in the joints, leading to pain, swelling, stiffness, and eventual joint damage. This condition occurs when the body's immune system mistakenly attacks the synovium, the lining of the membranes surrounding the joints. Treatment focuses on reducing inflammation, alleviating pain, and preventing joint damage through a combination of medications, physical therapy, and lifestyle modifications. Recently, biological therapies have been introduced, including Tumour Necrosis Factor (TNF) blockers (such as etanercept, infliximab, and adalimumab), IL-6 inhibitors (tocilizumab), and interleukin- 1 inhibitors (anakinra). These treatments can lead to various side effects. The use of herbalbased treatments, such as secondary metabolites, has gained popularity due to their better tolerability, safety, and effectiveness compared to conventional therapies. However, there are also some limitations, like poor bioavailability and permeability and lower stability; to overcome these issues, Novel Drug Delivery Systems (NDDS) have been introduced as better treatment options in recent years. Polymer science advancements and nanotechnology applications have opened new avenues for RA treatment, emphasizing the development of smart drug delivery systems. These systems aim to improve therapeutic outcomes while minimizing adverse effects. Additionally, newly synthesized biocompatible drug delivery systems, combined with anti-inflammatory drugs composed of secondary metabolites, offer potential solutions for RA.

Periodontitis (PD) is a pathological condition that results in chronic swelling in the tissue around a tooth, which results in advanced periodontal structural injury to the encircling soft and hard tissues with eventual exfoliation and movement of teeth. It affects around 60% of the world's population, indicating a relatively high prevalence. Therefore, the discovery of efficient therapeutic interventions for dental disorders is a primary goal of the health sciences, and periodontitis is a significant public health problem. Currently, perioceutics plays a revolutionary role in periodontal therapy with the introduction of both systemic and local route administration of therapeutic drugs as supportive therapy to SRP (Scaling and Root Planning). The key to effective periodontal treatment is the selection of the proper antibacterial agent and the local route of medication delivery. The items mentioned, including irrigation systems, gels, fibers, films, thin strips, microvesicles, zero-dimensional nanomaterial, and moderate-dose biocide agents, reflect the innovative site-specific drug delivery available in the sector, resulting in the fulfillment of antimicrobial substances to sites of periodontal disease with low to non-existent negative impacts on other bodily systems. The current report seeks to present the most recent technologies in local biomaterial-based delivery with different properties that play a significant role in gum disease so that the practitioners are able to select appropriate bioactive agents for LDDS that are custom-tailored for a given clinical condition, identify present obstacles, and determine the future research opportunities.

Alzheimer's disease (AD) is an irreversible brain disorder that led to memory loss and disrupts daily life. Earlier strategies to treat AD such as acetylcholinesterase inhibitor (AChEI) drugs are not showing effectiveness due to the inability to cross the blood-brain barrier. Moreover, traditional AChEI provides limited efficacy in terms of bioavailability and solubility for treating AD treatment. Many of the current drugs such as donepezil taken to treat the disease exhibited harmful side effects. Hence, researchers are keen to find the alternative effective therapeutic agents for treating AD. This review summarizes the recent advancement in nanotechnology-based drug delivery systems of herbal drugs such as Curcumin, Ginkgo biloba, Salvia officinalis, etc for the prevention and cure of AD. Herbal drugs proved useful in treating neuronal disorders such as AD but exhibited some limitations like low bioavailability via oral drug delivery. Such limitations were overcome by tagging these drugs by nanoparticles which enables them to cross the blood-brain barrier and offer the delivery of greater concentration of herbal drugs to the brain. Inorganic nanoparticle-based drugdelivery systems such as gold nanoparticles and magnetic nanoparticles, organic nanoparticulate systems like polymeric micelles and dendrimers, and solid polymeric nanoparticles were some of the effective methods that have earlier shown potential for enhancing the delivery of herbal drugs to the brain. Long-term repeated injection of drugs loaded on nanomaterials can lead to the accumulation of nanomaterials in the body without timely and effective degradation which can cause serious issues to the brain. Hence, nanotechnology-based strategies should involve the formulation of nontoxic nanoparticles in such a way that they can significantly transport the drugs across the BBB followed by effective degradation of nanoparticles.

Introduction: Metal nanoparticles have received much attention due to their unique physical dynamics, chemical reactivity, and promising biological applications. Green synthesis using natural compounds is an alternative to traditional chemical methods for the synthesis of nanoparticles.

Materials and methods: Herein, two secondary metabolites were isolated from different fractions of methanolic extract of Citrullus colocynthis (bitter apple) Schard. and identified as cucurbitacin Eglycoside (1) and methyl gallate (2). Both compounds were used in the green nanoformulation of gold nanoparticles. Mass spectrometry and NMR spectroscopy were used for structure elucidation of compound 1 and compound 2. UV-vis spectroscopy, FTIR, and AFM were performed to confirm the formation of AuNPs.

Result and discussions: The spectra of UV-Vis showed a characteristic peak at 519 nm and 548 nm for compounds 1 and 2, respectively. AuNPs ranged mostly between 1 and 50 nm measured using AFM. The FTIR analysis confirmed the presence of phytochemicals on the surface of AuNPs. The synthesized AuNPs showed good antibacterial activity against Escherichia coli, Bacillus subtilis, and Pseudomonas aeruginosa.

Conclusion: The synthesized AuNPs demonstrated good antibiofilm activity against Streptococcus mutans. Thus, the green synthesized AuNPs can combat the pathogenicity of several human pathogens.

Nanotechnology is rapidly transforming various fields, including medicine, environmental conservation, agriculture, and pharmaceuticals. The production of metallic nanoparticles is a key area within this field, known for its innovative applications. However, traditional chemical and physical methods used for nanoparticle synthesis often involve toxic chemicals and are expensive, making them unsuitable for large-scale production. To address these issues, there has been a growing focus on developing sustainable, cost-effective, and eco-friendly methods. One promising approach is the biological synthesis of metallic nanoparticles. This technique combines principles from biology and nanotechnology, using natural sources such as plant extracts, bacteria, fungi, yeast, and algae to produce nanoparticles in an environmentally friendly way. This review examines the biological synthesis of various metal nanoparticles, including platinum, palladium, gold, and silver. It explores different green methods used for their production and discusses the mechanisms that enable these biological processes. Additionally, the review highlights the diverse applications of these nanoparticles, from environmental cleanup and heavy metal removal to cancer treatment and drug delivery. By focusing on green synthesis methods, this approach not only reduces environmental impact but also offers a scalable, sustainable alternative to traditional nanoparticle production techniques. As research in this area advances, these eco-friendly methods are expected to play a crucial role in the future of nanotechnology.

Breast cancer poses a formidable challenge due to its inherent difficulty in treatment. Recognizing the imperative need for new therapeutic approaches, this study focuses on a groundbreaking technique that has the potential to reshape breast cancer treatment: siRNA formulations based on lipid nanoparticles (LNPs). This novel method holds promise for transforming the landscape of breast cancer therapy. The primary objective of this research is to conduct a comprehensive assessment of the current state of the art in the field, specifically exploring the potential applications of siRNA treatments encapsulated in LNPs for breast cancer. The research methodology involves a detailed literature review covering breast cancer, siRNA therapy, and lipid nanoparticles. The study investigates the fundamental principles of siRNA therapy, highlighting its capacity to selectively silence genes critical to breast cancer development. Additionally, the application of LNPs in delivering therapeutic siRNA payloads is explored, with an emphasis on the benefits of LNPs, including their biocompatibility and effective siRNA incorporation. Safety and effectiveness characteristics of LNP-based siRNA formulations are also assessed to pave the way for potential therapeutic applications. Findings from the study illuminate the promising characteristics of LNP-siRNA formulations in the treatment of breast cancer. The investigation provides insights into targeting strategies, such as the enhanced permeability and retention (EPR) effect and the utilization of ligand-conjugated nanoparticles. The study outlines potential avenues for therapeutic use, drawing attention to the safety and effectiveness of LNP-based siRNA formulations. In summary, this study aims to reveal intricate interactions between lipid nanoparticle-based siRNA formulations and breast cancer treatment, fostering a transformation in the field by highlighting current developments, future trends, and innovative strategies for next-gen LNP-based siRNA formulations.

Background: Currently, a large number of populations are suffering from diabetes mellitus, which significantly increases the burden on public health. Glimepiride is an antidiabetic drug with a shorter half-life (approximately 5 hours), low bioavailability, and first-pass metabolism. Due to these limitations, it is required to maintain a uniform therapeutic level, and it has been chosen as a transdermal drug delivery approach.

Objectives: The main objective of this investigation was to evaluate glimepiride-loaded transdermal patches on the skin to treat diabetes mellitus. To overcome the issue of oral glimepiride and provide a localized effect, a transdermal drug delivery approach was developed.

Methods: The glimepiride transdermal drug delivery approach was developed by using the solvent evaporation method. To examine the impact of altering amounts of polyvinyl alcohol (X1) and polyvinyl pyrrolidone (X2) on tensile strength, % of glimepiride released in 12 hours (Q12), and % of glimepiride released in 24 hours (Q24), as reliant on variables, a 32 complete factorial design was employed. For dependent variables, regression estimation and estimation of variance were employed. In-vitro release statistics were fixed to different models for various glimepiride release kinetics. In-vitro glimepiride release was tested using the best formulation.

Results: The formulation F4 with 1300.00 milligrams of polyvinyl alcohol and 600.00 milligrams of polyvinyl pyrrolidone demonstrated a release of 96.17% for up to 24 hours and zero order release kinetics consisting of r2=0.987, which was the best batch. The optimized formulation F4 showed a controlled release of glimepiride and better permeation and deposition properties.

Conclusion: The findings of this research work demonstrated the potential of the 32 full factorial mathematical models created to anticipate formulations with additional desirable release and permeability qualities for the treatment of diabetes mellitus.

Background: Bacterial nanocellulose (BNC) is typically produced through fermentation using Hestrin Schramm (HS) médium. However, its high cost limits its use in industry. Moreover, curcumin, as a model substance, is a potential bioactive compound but has low bioavailability. This also limits its use for clinical application. Thus, a delivery system using more affordable production of BNC was develop to improve the lack property of curcumin, focusing on topical route.

Objective: This study aims to determine the best substrate component according to yield value and evaluate the physical properties as well as the permeation capability of BNC as a delivery matrix system for curcumin.

Methods: The optimization of Gluconacetobacter xylinus culture media to produce BNC was conducted using 6 variation substrates consisting of Palmyra sap (PS) and tofu pulp with certain concentrations. Following a nine-day period, the yield of BNC was calculated. The selected BNCs were then impregnated with curcumin-DMSO and curcumin in the form of nanoemulsion (curcumin- NE). Subsequently, the BNCs containing these curcumin forms were characterized. In vitro testing of curcumin reléased from BNC was conducted using Franz difusión cells. In addition, the penetration ability of curcumin across the mice skin was observed using confocal microscopy. In vivo testing was also conducted to ascertain the safety of BNC-loaded curcumin on mice skin.

Results: PS-TP substrate (100:0, S-6) was the most appropriate substrate for BNC production, yielding 118.5±0.09 g/L. CR-DMSO and CR-NE were successfully impregnated into BNC. Confocal data showed that both formulations were able to penétrate the dermis layer. There was no significant difference was observed between the administration of BNC/CR-DMSO and BNC/CR-NE against the control.

Conclusion: BNC successfully produced using palmyra sap shows promising biomembrane for topical delivery of curcumin. No evidence inflammation or neovascularization in BNC/CR-DMSO- and BNC/CR-NE-treated mice confirms the safety use of this biomembrane.

Transdermal drug delivery systems (TDDS) have emerged as a popular non-invasive approach for treating skin-related disorders, offering quick and reliable drug delivery into the skin, thereby accelerating therapeutic efficacy. In India, there is a growing interest in TDDS due to its perceived safety and effectiveness. Researchers are actively developing new formulations and technologies to enhance drug delivery efficiency and reduce side effects. Recent trends indicate a focus on overcoming challenges such as low permeability and stability issues through innovative nanoparticle-based delivery systems. Nanotechnology has revolutionized transdermal drug delivery by offering precise control over nanoparticle properties, enabling enhanced skin permeation and targeted delivery. Various nanoparticle formulations, including polymeric nanoparticles, liposomes, nanotubes, solid lipid nanoparticles, and nanoemulsions, have shown promise in improving drug solubility, bioavailability, and sustained release. Additionally, microneedles have emerged as a successful transdermal delivery method, offering advantages over traditional creams and patches. Metallic nanocarriers and nanoemulsions are also being explored for their potential in targeted drug delivery and enhanced skin penetration. Despite these advancements, challenges such as toxicity and biocompatibility need to be addressed for widespread clinical translation. Overall, the growing interest in transdermal drug delivery systems in India reflects the potential for improved therapeutic outcomes and patient convenience through innovative nanoparticle- based formulations and technologies.